| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.17 | 0.0004 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0005 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0005 |